<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended April 30, 1997
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________________ to ______________
Commission File Number 1-8366
-------
POLYDEX PHARMACEUTICALS LIMITED
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Commonwealth of the Bahamas None
- ------------------------------ -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
421 Comstock Road, Scarborough, Ontario, Canada M1L 2H5
- --------------------------------------------------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code (416) 755-2231
--------------
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
------ ------
Indicate the number of shares outstanding of each of the issuer's
classes of common shares, as of the latest practicable date.
Common Shares, $.00167 Par Value 28,252,182
- -------------------------------- -----------------------------
(Title of Class) (Outstanding at June 6, 1997)
<PAGE> 2
POLYDEX PHARMACEUTICALS LIMITED
-------------------------------
TABLE OF CONTENTS
PAGE
----
PART I FINANCIAL INFORMATION
Item 1 CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Consolidated Balance Sheets 3
April 30, 1997 and January 31, 1997
Consolidated Statements of Operations 5
Three Months ended April 30, 1997 and 1996
Consolidated Statements of Shareholders' Equity 6
Three Months ended April 30, 1997 and 1996
Consolidated Statements of Cash Flows 7
Three Months ended April 30, 1997 and 1996
Item 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF 8
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
PART II OTHER INFORMATION
Item 6 EXHIBITS AND REPORTS ON FORM 8-K 10
Signatures
11
-2-
<PAGE> 3
PART I - FINANCIAL INFORMATION
------------------------------
POLYDEX PHARMACEUTICALS LIMITED AND
SUBSIDIARIES
<TABLE>
<CAPTION>
Consolidated Balance Sheets
(Expressed in United States dollars)
- ---------------------------------------------------------------------------------------
(Unaudited)
April 30 January 31
1997 1997
- ---------------------------------------------------------------------------------------
<S> <C> <C>
ASSETS
Current Assets:
Cash $ 516,226 $ 603,491
Trade accounts receivable, net of allowance 788,837 1,107,829
Interest receivable 2,517 -
Inventories:
Finished goods 851,719 656,039
Work in process 28,434 89,640
Raw materials 538,726 533,601
---------------------------------------------------------------------------------
1,418,879 1,279,280
Prepaid expenses and other current assets 61,825 63,312
------------------------------------------------------------------------------------
2,788,284 3,053,912
Property, plant and equipment, at cost
Land and buildings 2,769,673 2,796,935
Machinery and equipment 4,999,497 5,077,720
------------------------------------------------------------------------------------
7,769,170 7,874,655
Less allowances for depreciation and amortization (3,992,763) (4,017,353)
------------------------------------------------------------------------------------
3,776,407 3,857,302
Patents and animal drug applications at cost, net of
accumulated amortization 851,391 877,311
Due from Novadex Inc. 769,032 765,209
Other assets 62,798 73,783
- ---------------------------------------------------------------------------------------
$ 8,247,912 $ 8,627,517
=======================================================================================
</TABLE>
-3-
<PAGE> 4
<TABLE>
<CAPTION>
===========================================================================================
(Unaudited)
April 30 January 31
1997 1997
- -------------------------------------------------------------------------------------------
<S> <C> <C>
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities $ 1,263,041 $ 1,511,698
Current portion of long-term debt 59,058 60,185
----------------------------------------------------------------------------------------
1,322,099 1,571,883
Long-term debt 505,234 524,656
Due to shareholders 606,172 605,475
Due to affiliated companies 425,420 425,420
Deferred gain 734,745 776,564
Minority interest 22,087 22,791
Shareholders' equity:
Capital stock:
Authorized:
1,000,000 A preferred shares of $0.01 each
8,994,000 B preferred shares of $0.00167 each
40,000,000 common shares of $0.00167 each
Issued and outstanding:
8,994,000 B preferred shares 15,010 15,010
28,252,182 common shares (January 31,
1997 - 28,252,182) of which 82,400 are
held in treasury 46,959 46,959
Contributed surplus 22,733,319 22,733,319
Deficit (17,565,806) (17,559,330
Currency translation adjustments (597,327) (535,230)
----------------------------------------------------------------------------------------
4,632,155 4,700,728
----------------------------------------------------------------------------------------
$ 8,247,912 $ 8,627,517
===========================================================================================
</TABLE>
-4-
<PAGE> 5
POLYDEX PHARMACEUTICALS LIMITED AND
SUBSIDIARIES
<TABLE>
<CAPTION>
Consolidated Statements of Operations (Unaudited)
(Expressed in United States dollars)
===============================================================================
Quarter Ended Quarter Ended
April 30 April 30
1997 1996
- -------------------------------------------------------------------------------
<S> <C> <C>
Sales $ 2,236,335 $ 2,246,960
Cost of products sold, exclusive of
depreciation reported below 1,584,905 1,676,753
- -------------------------------------------------------------------------------
651,430 570,207
Expenses:
Selling and promotion 67,658 27,774
General and administrative 389,967 316,743
Depreciation and amortization 144,592 143,211
Interest expense 29,018 39,169
Research and development 38,371 60,834
----------------------------------------------------------------------------
669,606 587,731
- -------------------------------------------------------------------------------
Profit (loss) from operations (18,176) (17,524)
Other income (expenses):
Interest and other 10,998 5,842
- -------------------------------------------------------------------------------
Profit (loss) before the undernoted (7,178) (11,682)
Provision for income taxes -- --
Minority interest in loss 702 --
- -------------------------------------------------------------------------------
Profit (loss) for the period $ (6,476) $ (11,682)
===============================================================================
Per share information:
Profit (loss) per common share:
For the period $ 0.00 $ 0.00
===============================================================================
</TABLE>
-5-
<PAGE> 6
POLYDEX PHARMACEUTICALS LIMITED AND
SUBSIDIARIES
<TABLE>
<CAPTION>
Consolidated Statements of Shareholders' Equity (Unaudited)
(Expressed in United States dollars)
========================================================================================
Quarter Ended Quarter Ended
April 30 April 30
1997 1996
- ----------------------------------------------------------------------------------------
<S> <C> <C>
Preferred Shares:
Balance, beginning of period $ 15,010 $ 15,010
Private placement of preferred shares - -
-----------------------------------------------------------------------------------
Balance, end of period $ 15,010 $ 15,010
========================================================================================
Common Shares:
Balance, beginning of period $ 46,959 $ 46,625
Exercise of options - -
-----------------------------------------------------------------------------------
Balance, end of period $ 46,959 $ 46,625
========================================================================================
Contributed Surplus:
Balance, beginning of period $ 22,733,319 $ 22,583,653
Exercise of options - -
-----------------------------------------------------------------------------------
Balance, end of period $ 22,733,319 $ 22,583,653
========================================================================================
Deficit:
Balance, beginning of period $(17,559,330) $(17,681,720)
Net income (loss) for the period (6,476) (11,682)
-----------------------------------------------------------------------------------
Balance, end of period $(17,565,806) $(17,693,402)
========================================================================================
Currency translation adjustments:
Balance, beginning of period $ (535,230) $ (522,851)
Currency translation adjustment for the period (62,097) 8,214
-----------------------------------------------------------------------------------
Balance, end of period $ (597,327) $ (514,637)
========================================================================================
</TABLE>
-6-
<PAGE> 7
POLYDEX PHARMACEUTICALS LIMITED AND
SUBSIDIARIES
Consolidated Statements of Cash Flows (Unaudited)
(Expressed in United States dollars)
<TABLE>
<CAPTION>
========================================================================
Quarter Ended Quarter Ended
April 30 April 30
1997 1996
- ------------------------------------------------------------------------
<S> <C> <C>
Cash provided by (used in):
Operating activities:
Profit (loss) for the period $ (6,476) $ (11,682)
Add (deduct) items not affecting cash:
Depreciation and amortization 144,592 143,211
Decrease in deferred gain (41,819) -
Minority interest (702) -
Change in non-cash operating working capital (87,459) (179,671)
---------------------------------------------------------------------
8,136 (48,142)
---------------------------------------------------------------------
Investing activities:
Additions to property, plant and equipment (39,103) (38,426)
Additions to patents and animal drug
applications - (1,100)
---------------------------------------------------------------------
(39,103) (39,526)
---------------------------------------------------------------------
Financing activities:
Repayment of long-term debt (20,549) (11,151)
Advances from (repayment to) shareholders 697 85,422
Advances from (repayment to) Novadex Inc. (3,823) -
Increase (decrease) in bank indebtedness - 7,630
---------------------------------------------------------------------
(23,675) 81,901
Effect of exchange rate changes on cash (32,623) (5,852)
- ------------------------------------------------------------------------
Increase (decrease) in cash position (87,265) (11,619)
Cash position, beginning of period 603,491 12,321
- ------------------------------------------------------------------------
Cash position, end of period $ 516,226 $ 702
========================================================================
</TABLE>
-7-
<PAGE> 8
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.
(a) RESULTS OF OPERATIONS
During the fiscal quarter ended April 30, 1997, the Registrant's pre-tax profit
from operations prior to research and development, interest charges and
depreciation amounted to $193,805, as compared to a similarly calculated pre-tax
profit of $225,690 for the same period last year. This change was primarily
composed of an increase in such profits at Dextran Products Limited ("Dextran")
of $145,819 offset by increased expenses at the corporate head office of $96,056
and a decline in such profits at Veterinary Laboratories Inc. ("Vet Labs") of
$79,029.
Sales volume this quarter decreased slightly from the same period last year by
$10,625. Dextran experienced a quarter over quarter increase in sales of $76,963
as a result of increased demand for its products, however this was offset by a
decrease at Vet Labs of $87,588 due to a decline in sales of Iron Dextran.
Competitors in this product began selling at reduced prices. Vet Labs attempted
to maintain their price level, however this significantly reduced the sales
volume and Vet Labs ultimately had to reduce the selling price in order to move
product.
Gross margins increased from 25% in the first quarter last year to 29% this
quarter. Dextran's quarter over quarter gross margin increased significantly
from 37% to 49% while Vet Labs' gross margin decreased from 13% to 8%. The
margin increase at Dextran was due to a decline in the average Canadian dollar
exchange rate, labour efficiencies achieved and sales mix. The decrease in
margin at Vet Labs was attributable to increased filtration costs, the reduced
sales of Iron Dextran, which is a higher margin product, and the reduction in
the selling price of Iron Dextran described above.
Selling and promotion expenses in the quarter increased by $39,884 as compared
to the first quarter last year due to contracting the services of a marketing
company to begin promotion of new products.
General and administrative expenses have increased by $73,224 as a result of
several factors. There was a general increase in salaries midway through the
prior year as well as a new position created when Dr. Alec Keith was hired
during the fourth quarter of last year to be the Chairman of the Board of
Directors and Mr. Thomas C. Usher assumed the new position of Vice-Chairman.
Legal and other fees associated with the preparation of SEC reports increased
also. This increase was due in large part to complexities associated with the
Registrant's proposed one-for-ten reverse stock split of its Common Shares and
Class B Preferred Shares to be voted on by shareholders
-8-
<PAGE> 9
at the Annual General Meeting on June 19, 1997, as well as increased costs of
complying with the SEC's new electronic filing system.
Research and development expenses have declined this quarter relative to the
same quarter in the prior year because of increased funding from government
sources.
Interest expenses have decreased by $10,151 compared to the same quarter last
year due in part to the refinancing of the mortgage payable on Dextran's plant.
Operating results for the first quarter ended April 30, 1997 are not necessarily
indicative of the results that may be expected for the year ended January 31,
1998. For further information, refer to the consolidated statements and
footnotes thereto included in the Registrant's annual report on Form 10-K for
the year ended January 31, 1997.
(b) LIQUIDITY AND CAPITAL RESOURCES
The Registrant in the first quarter generated a positive cash flow from
operations of $8,136 compared to the prior year first quarter negative cash flow
from operations of $48,142. This increase in working capital is primarily due to
the collection of year end accounts receivable. Accounts receivable at Dextran
decreased from $563,041 at the previous year end to $432,391, while Vet Labs'
receivable balance decreased from $560,139 at the previous year end to $356,446.
This large increase in working capital generated was partially offset by an
increase in inventory levels. Inventory at Dextran increased from the year end
balance of $604,122 to $693,366 at the end of the first quarter. The inventory
level at Vet Labs remained constant during the quarter. Dextran is increasing
their inventory levels in case of any production interruptions during the
anticipated plant refurbishment later this year.
Positive operational cash flows are expected to continue in the future, but
should the need for further cash infusions arise, the Registrant believes that
continued loans and/or capital contributions from principal shareholders will
meet these requirements.
The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting
of normally recurring accruals) considered necessary for a fair presentation
have been included.
-9-
<PAGE> 10
PART II - OTHER INFORMATION
---------------------------
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
3.1 Memorandum of Association of Polydex Pharmaceuticals
Limited, as amended (filed as Exhibit 3.1 to the
Annual Report on Form 10-K filed April 30, 1997, and
incorporated herein by reference)
3.2 Articles of Association of Polydex Pharmaceuticals
Limited, as amended (filed as Exhibit 3.2 to the
Annual Report on Form 10-K filed April 30, 1997, and
incorporated herein by reference)
27 Financial Data Schedule
(b) Reports on Form 8-K
April 2, 1997 - Item 4. Changes in Registrant's
Certifying Accountant. On December 18, 1996, the
Registrant engaged Ernst & Young LLP as its new
independent accountants to audit its financial
statements for the fiscal year ended January 31,
1997. The Registrant reported the engagement of Ernst
& Young LLP on a Form 8-K dated April 2, 1997.
-10-
<PAGE> 11
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: June 10, 1997
POLYDEX PHARMACEUTICALS LIMITED
(Registrant)
By /s/ George G. Usher
-----------------------------------------
George G. Usher, President and Chief
Executive Officer
(Principal Executive Officer)
By /s/ Sharon Wardlaw
-----------------------------------------
Sharon Wardlaw, Treasurer, Secretary and
Chief Financial and Accounting Officer
(Principal Financial Officer)
-11-
<PAGE> 12
EXHIBIT INDEX
Exhibit Number Exhibit Description
- -------------- -------------------
27 Financial Data Schedule
-12-
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> JAN-31-1998
<PERIOD-START> FEB-01-1997
<PERIOD-END> APR-30-1997
<CASH> 516,226
<SECURITIES> 0
<RECEIVABLES> 788,837
<ALLOWANCES> 0
<INVENTORY> 1,418,879
<CURRENT-ASSETS> 2,788,284
<PP&E> 7,769,170
<DEPRECIATION> 3,992,763
<TOTAL-ASSETS> 8,247,912
<CURRENT-LIABILITIES> 1,322,099
<BONDS> 505,234
<COMMON> 46,959
0
15,010
<OTHER-SE> 22,733,319
<TOTAL-LIABILITY-AND-EQUITY> 8,247,912
<SALES> 2,236,335
<TOTAL-REVENUES> 2,236,335
<CGS> 1,584,905
<TOTAL-COSTS> 1,584,905
<OTHER-EXPENSES> 669,606
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 29,018
<INCOME-PRETAX> (6,476)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (6,476)
<EPS-PRIMARY> 0
<EPS-DILUTED> 0
</TABLE>
